niacin has been researched along with Chronic Kidney Diseases in 14 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations." | 5.19 | Effect of niacin on FGF23 concentration in chronic kidney disease. ( Bostom, A; Ix, JH; Rao, M; Steffes, M, 2014) |
| " However, niacin can cause flushing and niacinamide probably cause thrombocytopenia." | 4.90 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014) |
| "Early-stage detection of chronic kidney diseases (CKD) is important to treatment that may slow and occasionally halt CKD progression." | 3.01 | The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease. ( Curran, CS; Kopp, JB, 2023) |
| "This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population." | 2.72 | Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021) |
| " As for safety end points (including mortality, adverse events, and all-cause discontinuation), almost all agents were equivalent in term of mortality and all-cause discontinuation except in the comparison between iron-based phosphate-binding agents and placebo." | 2.58 | Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( Bai, Q; Guo, H; Li, Y; Liu, H; Yang, X; Zhang, X, 2018) |
| "Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract." | 2.52 | Niacin and progression of CKD. ( Kalantar-Zadeh, K; Kashyap, ML; Kovesdy, CP; Moradi, H; Streja, DA; Streja, E, 2015) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kędzierska-Kapuza, K | 1 |
| Szczuko, U | 1 |
| Stolińska, H | 1 |
| Bakaloudi, DR | 1 |
| Wierzba, W | 1 |
| Szczuko, M | 1 |
| Curran, CS | 1 |
| Kopp, JB | 1 |
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Mathew, RO | 2 |
| Rosenson, RS | 1 |
| Lyubarova, R | 1 |
| Chaudhry, R | 1 |
| Costa, SP | 1 |
| Bangalore, S | 1 |
| Sidhu, MS | 1 |
| Yang, X | 1 |
| Bai, Q | 1 |
| Li, Y | 1 |
| Liu, H | 1 |
| Guo, H | 1 |
| Zhang, X | 1 |
| Drüeke, TB | 1 |
| Massy, ZA | 1 |
| Streja, E | 2 |
| Streja, DA | 2 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 2 |
| Khoueiry, G | 1 |
| Abdallah, M | 1 |
| Saiful, F | 1 |
| Abi Rafeh, N | 1 |
| Raza, M | 1 |
| Bhat, T | 1 |
| El-Sayegh, S | 1 |
| Kalantar-Zadeh, K | 2 |
| Lafferty, J | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Rao, M | 1 |
| Steffes, M | 1 |
| Bostom, A | 1 |
| Ix, JH | 2 |
| Kalil, RS | 1 |
| Wang, JH | 1 |
| de Boer, IH | 1 |
| Asif, A | 1 |
| Shi, X | 1 |
| Boden, WE | 1 |
| Kovesdy, CP | 1 |
| Kashyap, ML | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| KNICK, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204] | Phase 3 | 1,620 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Demand for Water-Soluble Vitamins in a Group of Patients with CKD versus Interventions and Supplementation-A Systematic Review.
Topics: Ascorbic Acid; Dietary Supplements; Folic Acid; Humans; Kidney Failure, Chronic; Niacin; Renal Dialy | 2023 |
The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease.
Topics: Basic Helix-Loop-Helix Transcription Factors; Humans; Hypoxia; Ischemia; NAD; Niacin; Receptors, Ary | 2023 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl- | 2021 |
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Topics: Bile Acids and Salts; Calcium; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Iron; | 2018 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Ag | 2014 |
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a | 2014 |
Niacin and progression of CKD.
Topics: Comorbidity; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Hypolipide | 2015 |
2 trials available for niacin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of niacin on FGF23 concentration in chronic kidney disease.
Topics: Aged; Calcium; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipid | 2014 |
Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Delayed-Action Preparations; Drug T | 2015 |
4 other studies available for niacin and Chronic Kidney Diseases
| Article | Year |
|---|---|
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Lowering Expectations with Niacin Treatment for CKD-MBD.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Minerals; Motivation; N | 2018 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |
[Nicotinic acid therapy of anuric disorders in acute & chronic renal insufficiency].
Topics: Acute Kidney Injury; Anuria; Humans; Kidney Diseases; Niacin; Nicotinic Acids; Renal Insufficiency, | 1959 |